CHRM3抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CHRM3 mouse mAb (green) and negative control (red).    

  
  

The CHRM3 antibody targets the M3 muscarinic acetylcholine receptor (CHRM3), a G protein-coupled receptor (GPCR) predominantly expressed in smooth muscles, exocrine glands, and the central nervous system. CHRM3 mediates acetylcholine signaling by coupling to Gq/11 proteins, activating phospholipase C, and increasing intracellular calcium levels. This receptor plays critical roles in regulating smooth muscle contraction (e.g., bronchial, gastrointestinal), glandular secretions (e.g., salivary, sweat), and metabolic processes like insulin release. Dysregulation of CHRM3 is implicated in disorders such as asthma, overactive bladder, and diabetes, making it a therapeutic target for anticholinergic drugs.

CHRM3 antibodies are essential tools for studying receptor localization, expression levels, and function in physiological or pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess CHRM3 distribution in tissues or cell lines. Some antibodies distinguish between phosphorylated (activated) and unphosphorylated forms, aiding in signaling pathway analysis. Challenges include ensuring specificity due to structural similarities among muscarinic receptor subtypes (M1-M5). Researchers must validate CHRM3 antibodies using knockout controls or blocking peptides to avoid cross-reactivity. Additionally, these antibodies support drug discovery by screening compounds targeting CHRM3 for conditions like chronic obstructive pulmonary disease (COPD) or urinary incontinence. Recent studies also explore CHRM3's role in cancer progression, particularly tumors with cholinergic autocrine signaling.